Altered ovarian function and cardiovascular risk factors in valproate-treated women

Jouko I.T. Isojari; Erik Tauboll; Arto J. Pakarinen; Johan van Parys; Johanna Rättyä; Hanne Flinstad Harbo; Per O. Dale; B.C.J.M. Fauser; Leif Gjerstad; Riitta Koivunen; Mikael Knip; Juha S. Tapanainen

doi:10.1016/S0002-9343(01)00806-3

Altered ovarian function and cardiovascular risk factors in valproate-treated women

Jouko I.T. Isojari
, Erik Tauboll
, Arto J. Pakarinen
, Johan van Parys
, Johanna Rättyä
, Hanne Flinstad Harbo
, Per O. Dale
, B.C.J.M. Fauser
, Leif Gjerstad
, Riitta Koivunen
, Mikael Knip
, Juha S. Tapanainen

Obstetrics & Gynecology

University Hospital Dijkzigt

Research output: Contribution to journal › Article › Academic › peer-review

136 Citations (Scopus)

Abstract

Purpose
Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy.
Subjects and methods
Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy.
Results
The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70% (26 of 37) compared with 19% (10 of 52) among control subjects (P <0.001). They were found in 79% (11 of 14) of obese and 65% (15 of 23) of lean women on valproate, and in 20% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance.
Conclusions
Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.

Original language	English
Pages (from-to)	290-296
Number of pages	7
Journal	American Journal of Medicine
Volume	111
Issue number	4
DOIs	https://doi.org/10.1016/S0002-9343(01)00806-3
Publication status	Published - Sept 2001

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-01-52-07

Access to Document

10.1016/S0002-9343(01)00806-3

Cite this

Isojari, J. I. T., Tauboll, E., Pakarinen, A. J., van Parys, J., Rättyä, J., Flinstad Harbo, H., Dale, P. O., Fauser, B. C. J. M., Gjerstad, L., Koivunen, R., Knip, M., & Tapanainen, J. S. (2001). Altered ovarian function and cardiovascular risk factors in valproate-treated women. American Journal of Medicine, 111(4), 290-296. https://doi.org/10.1016/S0002-9343(01)00806-3

@article{27dfc53744d045658cd21f2513c9e5a7,

title = "Altered ovarian function and cardiovascular risk factors in valproate-treated women",

abstract = "Purpose Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy. Subjects and methods Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy. Results The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70\% (26 of 37) compared with 19\% (10 of 52) among control subjects (P <0.001). They were found in 79\% (11 of 14) of obese and 65\% (15 of 23) of lean women on valproate, and in 20\% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance. Conclusions Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.",

author = "Isojari, \{Jouko I.T.\} and Erik Tauboll and Pakarinen, \{Arto J.\} and \{van Parys\}, Johan and Johanna R{\"a}tty{\"a} and \{Flinstad Harbo\}, Hanne and Dale, \{Per O.\} and B.C.J.M. Fauser and Leif Gjerstad and Riitta Koivunen and Mikael Knip and Tapanainen, \{Juha S.\}",

note = "{\textcopyright}2001 by Excerpta Medica, Inc.",

year = "2001",

month = sep,

doi = "10.1016/S0002-9343(01)00806-3",

language = "English",

volume = "111",

pages = "290--296",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Altered ovarian function and cardiovascular risk factors in valproate-treated women

AU - Isojari, Jouko I.T.

AU - Tauboll, Erik

AU - Pakarinen, Arto J.

AU - van Parys, Johan

AU - Rättyä, Johanna

AU - Flinstad Harbo, Hanne

AU - Dale, Per O.

AU - Fauser, B.C.J.M.

AU - Gjerstad, Leif

AU - Koivunen, Riitta

AU - Knip, Mikael

AU - Tapanainen, Juha S.

PY - 2001/9

Y1 - 2001/9

N2 - Purpose Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy. Subjects and methods Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy. Results The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70% (26 of 37) compared with 19% (10 of 52) among control subjects (P <0.001). They were found in 79% (11 of 14) of obese and 65% (15 of 23) of lean women on valproate, and in 20% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance. Conclusions Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.

AB - Purpose Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy. Subjects and methods Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy. Results The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70% (26 of 37) compared with 19% (10 of 52) among control subjects (P <0.001). They were found in 79% (11 of 14) of obese and 65% (15 of 23) of lean women on valproate, and in 20% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance. Conclusions Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.

UR - https://www.researchgate.net/publication/11782562_Altered_ovarian_function_and_cardiovascular_risks_in_valproate_treated_women

UR - https://www.amjmed.com/article/S0002-9343(01)00806-3/fulltext

U2 - 10.1016/S0002-9343(01)00806-3

DO - 10.1016/S0002-9343(01)00806-3

M3 - Article

C2 - 11566460

SN - 0002-9343

VL - 111

SP - 290

EP - 296

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 4

ER -

Altered ovarian function and cardiovascular risk factors in valproate-treated women

Abstract

Bibliographical note

UN SDGs

Research programs

Access to Document

Other files and links

Fingerprint

Cite this